Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

DTaP-IPV-Hib

Phase 3Biologic

Sinovac Biotech Co., Ltd

DTaP-IPV-Hib is one of 20 biologic programs targeting Diphtheria. It is currently in Phase 3.

1

Indications

2

Total Trials

2

Active Trials

19

Competitors

Pipeline

Status by Indication[3][1]

Indication

DiphtheriaActive, not recruiting

DiphtheriaPhase 3

Active, not recruiting

Competition

Competitive Landscape

70 competitors in Diphtheria

#DrugCompanyPhaseTrials

Comparator: Pbo

Rotarix ™

Rotateq

Menactra

GSK 257049

Infanrix

Havrix

Rsvpref3 Vaccine

Acthib

REVAXIS

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diphtheria1 trial

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)

Active, not recruiting· CanSino Biologics Inc. logo

CanSino Biologics Inc.·Phase 3·NCT05951725·2,520 enrolled

Adolescent1 trial

Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations

Recruiting· Sinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd·Phase 4·NCT07354269·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for DTaP-IPV-Hib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DTaP-IPV-Hib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DTaP-IPV-Hib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sinovac Biotech Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Sinovac Biotech Co., Ltd

Related News